financetom
Personal Finance
financetom
/
Personal Finance
/
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Research Alert: CFRA Reiterates Buy Opinion On Shares Of Nutanix, Inc.
Mar 4, 2024 11:01 PM

01:00 PM EST, 02/29/2024 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target to $71 from $47 on a P/S of 7.5x, above its three-year average on good sales execution and a favorable deal pipeline, using our next-12-month sales estimate of $2.3B. We lift our FY 24 EPS view to $1.07 from $0.95 and FY 25's to $1.33 from $1.21. NTNX posted Q2 sales of $565.2M, above consensus by $14.8M, while non-GAAP EPS of $0.46 beat by $0.17. Revenue rose 16.2% Y/Y from solid Subscription revenue growth (+18% Y/Y) as ACV billings outperformed, up 23% Y/Y, from higher-than-anticipated renewals. We note NTNX's commentary around a continued uncertain macro environment, and longer average sales cycles, which likely impacted contract duration of 2.8 years in Q2, lower than Q1. However, these results reflect the firm's strong execution in securing and keeping pace with renewals and expansion deals, as well as maintaining healthy pricing levels in spite of these challenges. Its upbeat guidance and a higher mix of large deals in the pipeline further support our positive view of the business.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Research Alert: CFRA Maintains Buy Opinion On Shares Of Jpmorgan Chase & Co.
Oct 14, 2025
12:20 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $340, applying a forward P/E of 15.5x, near the three-year historical average at 15.0x on normalized earnings. We keep our EPS estimates at...
Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of The Goldman Sachs Group
Research Alert: CFRA Reiterates Strong Buy Opinion On Shares Of The Goldman Sachs Group
Oct 14, 2025
02:40 PM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We keep our 12-month target price at $850, applying a forward P/E of 15.6x our 2026 earnings estimate compared to the five-year historical average for normalized EPS at 15.5x. We...
Research Alert: CFRA Keeps Buy Opinion On Shares Of Blackrock, Inc.
Research Alert: CFRA Keeps Buy Opinion On Shares Of Blackrock, Inc.
Oct 14, 2025
12:30 AM EDT, 10/15/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We raise our 12-month target price by $95, to $1,340, valuing BLK shares at 22x our newly initiated 2027 adjusted EPS estimate of $60.50, and at 25x our 2026 EPS...
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Research Alert: CFRA Raises Opinion On Shares Of Johnson & Johnson To Buy From Hold
Oct 14, 2025
11:05 AM EDT, 10/14/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: After Q3 earnings and the announcement of the separation of Orthopedics, we raise our target to $220 from $166. This is based on 19.2x our 2026 EPS estimate and is...
Copyright 2023-2026 - www.financetom.com All Rights Reserved